Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697350 | 0.81 | ATM (0.42) | CRHR1 | |
| SCHEMBL4704335 | 0.79 | MEN1 (0.40) | LCKBRD9MAPK14 | |
| SCHEMBL3362569 | 0.77 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL3364499 | 0.76 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL3364390 | 0.76 | CRHR1 (0.40) | NPSR1CRHR1 | |
| SCHEMBL4700361 | 0.73 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL4697890 | 0.73 | CRHR1 (0.48) | CYP2C19NPSR1CRHR1 | |
| SCHEMBL3364082 | 0.72 | CRHR1 (0.45) | CRHR1 | |
| Hydrochloric Acid SCHEMBL6186878 | 0.72 | CRHR1 (0.47) | CYP2C19NPSR1CRHR1 | |
| SCHEMBL7592731 | 0.71 | LCK (0.41) | LCKCYP2C9CYP2C19NPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569911-B1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | LCK 3043/4885NSD2 2747/4885CYP2C9 385/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | LCK 3004/4885NSD2 2528/4885CYP2C9 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.